Dasatinib treatment for Philadelphia chromosome-positive Leukemias: practical considerations

Simple item page
dc.contributor.authorKhoury, H.
dc.contributor.authorGuilhot, F.
dc.contributor.authorHughes, T.
dc.contributor.authorKim, D.
dc.contributor.authorCortes, J.
dc.date.issued2009
dc.description.abstractDasatinib is a highly potent Bcr-Abl inhibitor that is approved for the treatment of imatinib-resistant or -intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. Across a series of phase 2 and 3 trials, dasatinib was associated with durable treatment responses in all phases of the disease and was well tolerated. For this article, the authors reviewed available information on specific side effects associated with the use of dasatinib. On the basis of more than 2 years' experience of dasatinib treatment during clinical trials, they provide practical recommendations for side-effect management.
dc.description.statementofresponsibilityHanna Jean Khoury, François Guilhot, Timothy P. Hughes, Dong-Wook Kim and Jorge E. Cortes
dc.identifier.citationCancer, 2009; 115(7):1381-1394
dc.identifier.doi10.1002/cncr.24155
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.orcidHughes, T. [0000-0002-0910-3730] [0000-0002-7990-4509]
dc.identifier.urihttp://hdl.handle.net/2440/60596
dc.language.isoen
dc.publisherJohn Wiley & Sons Inc
dc.rightsCopyright © 2009 American Cancer Society
dc.source.urihttps://doi.org/10.1002/cncr.24155
dc.subjectdasatinib
dc.subjectchronic myeloid leukemia
dc.subjectside effects
dc.subjectimatinib
dc.titleDasatinib treatment for Philadelphia chromosome-positive Leukemias: practical considerations
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications